Responses
Oncolytic and local immunotherapy
Original research
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.